Abstract
Detectable prostate-specific antigen (PSA) following radical prostatectomy for prostate cancer is seen in 25% to 35% of patients. Such biochemical recurrence represents a clinical dilemma, as it potentially represents either local or local and systemic disease. Prospective evidence supports the use of salvage radiotherapy (SRT) in this setting, but when to administer SRT is unclear. Now, investigators at a single academic center have assessed outcomes …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
